Flagging clinical adverse experiences: Reducing false discoveries without materially compromising power for detecting true signals

Statistics in Medicine

Volumn 31, Issue 18, 2012, Pages 1918-1930

  Mehrotra, Devan V ^a   Adewale, Adeniyi J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adverse experience; Body system; False discovery rate; False positive; Multiplicity adjustment; Safety analysis

Indexed keywords

ADVERSE OUTCOME; ANALYTICAL PARAMETERS; ARTICLE; CAUSAL ATTRIBUTION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; FALSE DISCOVERY RATE; FALSE POSITIVE RESULT; GENETIC ASSOCIATION; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEHROTRA HEYSE TUKEY METHOD; OUTCOME ASSESSMENT; PATIENT SAFETY; RISK ASSESSMENT; SIGNAL DETECTION; STATISTICAL ANALYSIS;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS;

EID: 84864011873     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5310     Document Type: Article

References (16)

1. Gould AL. Detecting potential safety issues in clinical trials by Bayesian screening. Biometrical Journal 2008 50: 837-851, DOI: 10.1002/bimj.200710469.
2. ICH Expert Working Group. ICH harmonized tripartite guideline: statistical principles for clinical trials. Statistics in Medicine 1999 18: 1905-1942.
3. Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL, Kuebler J, Schriver RC, Santanello NC, Rochester G, Porter JB, Oster M, Mehrotra DV, Li Z, King EC, Harpur ES, Hall DB. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clinical Trials 2009 6: 430-440, DOI: 10.1177/1740774509344101.
4. Kaplan KJ, Rusche SA, Lakkis HD et al. Post-licensure comparative study of unusual high-pitched crying and prolonged crying following COMVAX™ and placebo versus PedvaxHIB™ and RECOMBIVAX™ in healthy infants. Vaccine 2002 21: 181-187.
5. Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics 2004 60: 418-426.
6. Mehrotra DV, Heyse JH. Use of the false discovery rate for evaluating clinical safety data. Statistical Methods in Medical Research 2004 13: 227-238, DOI: 10.1191/0962280204sm363ra.
7. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 1995 57: 289-300.
8. Hu JX, Zhao H, Zhou HH. False discovery rate control with groups. Journal of the American Statistical Association 2010 105: 1215-1227, DOI: 10.1198/jasa.2010.tm09329.
9. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics 2001 29: 1165-1188, DOI: 10.1214/aos/1013699998.
10. Calian V, Li D, Hsu JC. Partitioning to uncover conditions for permutation tests to control multiple testing error rates. Biometrical Journal 2008 50: 756-766, DOI: 10.1002/bimj.200710471.
11. Heller R, Golland Y, Malach R, Benjamini Y. Conjunction group analysis: an alternative to mixed/random effect analysis. NeuroImage 2007 37: 1178-1185.
12. Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 2006 93: 491-507, DOI: 10.1093/biomet/93.3.491.
13. Miettinen OS, Nurminen M. Comparative analysis of two rates. Statistics in Medicine 1985 4: 213-226, DOI: 10.1002/sim.4780040211.
14. Lunn AD, Davies SJ.A note on generating correlated binary variables. Biometrika 1998 85: 487-490, DOI: 10.1093/biomet/85.2.487.
15. Mehrotra DV, Li X, Gilbert PB.A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics 2006 62: 893-900.
16. Liu GF, Wang J, Liu K, Snavely DB. Confidence intervals for an exposure adjusted incidence rate difference with applications in clinical trials. Statistics in Medicine 2006 25: 1275-1286, DOI: 10.1002/sim.2335.